Omalizumab Biosimilar Shows QoL Gains in CSU Phase 3 Post Hoc Data
Post hoc Phase 3 data presented at ACAAI 2026 show 44.4% of CSU patients on CT-P39 reached complete response with no QoL impact at Week 24, with gains persisting 16 weeks off treatment.